Intermittent chemotherapy in metastatic androgen-independent prostate cancer

T. M. Beer; M. Garzotto; W. D. Henner; K. M. Eilers; E. M. Wersinger

doi:10.1038/sj.bjc.6601232

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

T. M. Beer, M. Garzotto, W. D. Henner, K. M. Eilers, E. M. Wersinger

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml^-1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml^-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

Original language	English (US)
Pages (from-to)	968-970
Number of pages	3
Journal	British Journal of Cancer
Volume	89
Issue number	6
DOIs	https://doi.org/10.1038/sj.bjc.6601232
State	Published - Sep 15 2003

Keywords

Calcitriol
Chemotherapy
Docetaxel
Prostate cancer
Vitamin D

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6601232

Cite this

@article{eae0a8c74c99467fbe9c336f152b829d,

title = "Intermittent chemotherapy in metastatic androgen-independent prostate cancer",

abstract = "Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml-1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.",

keywords = "Calcitriol, Chemotherapy, Docetaxel, Prostate cancer, Vitamin D",

author = "Beer, {T. M.} and M. Garzotto and Henner, {W. D.} and Eilers, {K. M.} and Wersinger, {E. M.}",

note = "Funding Information: This work was supported in part by Grant GIA US 16066 from Aventis Pharmaceuticals and Grant 3M01RR00334-33S2 from the National Institutes of Health. Calcitriol was supplied by Roche Laboratories Inc.",

year = "2003",

month = sep,

day = "15",

doi = "10.1038/sj.bjc.6601232",

language = "English (US)",

volume = "89",

pages = "968--970",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Intermittent chemotherapy in metastatic androgen-independent prostate cancer

AU - Beer, T. M.

AU - Garzotto, M.

AU - Henner, W. D.

AU - Eilers, K. M.

AU - Wersinger, E. M.

N1 - Funding Information: This work was supported in part by Grant GIA US 16066 from Aventis Pharmaceuticals and Grant 3M01RR00334-33S2 from the National Institutes of Health. Calcitriol was supplied by Roche Laboratories Inc.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml-1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

AB - Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml-1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

KW - Calcitriol

KW - Chemotherapy

KW - Docetaxel

KW - Prostate cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=0141956345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141956345&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601232

DO - 10.1038/sj.bjc.6601232

M3 - Article

C2 - 12966410

AN - SCOPUS:0141956345

SN - 0007-0920

VL - 89

SP - 968

EP - 970

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this